• 1. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 2. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 3. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 4. Aggregation-induced chiroptical generation and photoinduced switching of achiral azobenzene-alt-fluorene copolymer endowed with left- and right-handed helical polysilanes?
  Hailing Chen,Lu Yin,Meng Liu,Laibing Wang,Michiya Fujiki,Wei Zhang RSC Adv., 2019,9, 4849-4856
• 5. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Halopyrimidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Halopyrimidines

Professional Introduction to 4-chloro-5-methyl-5,7-dihydrofuro[3,4-d]pyrimidine (CAS No. 1000984-97-3)

4-chloro-5-methyl-5,7-dihydrofuro[3,4-d]pyrimidine, with the CAS number 1000984-97-3, is a significant compound in the field of pharmaceutical chemistry and drug development. This heterocyclic compound belongs to the pyrimidine family, which is well-known for its diverse biological activities and therapeutic applications. The structural features of this molecule, particularly the presence of a chloro substituent and a methyl group, contribute to its unique chemical properties and reactivity, making it a valuable intermediate in synthetic chemistry.

The compound’s molecular structure consists of a fused ring system comprising a furan ring and a pyrimidine ring. This fused system imparts specific electronic and steric properties that are exploited in various chemical transformations. The 4-chloro substituent at the fourth position of the pyrimidine ring enhances its reactivity towards nucleophilic substitution reactions, while the 5-methyl group influences its electronic distribution and potential interactions with biological targets. These structural attributes make 4-chloro-5-methyl-5,7-dihydrofuro[3,4-d]pyrimidine a versatile building block for the synthesis of more complex pharmacophores.

In recent years, there has been growing interest in the development of novel pyrimidine derivatives as potential therapeutic agents. The compound 4-chloro-5-methyl-5,7-dihydrofuro[3,4-d]pyrimidine has been investigated for its potential applications in various therapeutic areas, including oncology, antiviral therapy, and immunomodulation. Its ability to serve as a precursor for more sophisticated molecules has made it a subject of extensive research in medicinal chemistry.

One of the most compelling aspects of this compound is its role in the synthesis of kinase inhibitors. Kinases are enzymes that play crucial roles in cell signaling pathways and are often implicated in diseases such as cancer. By modifying the structure of 4-chloro-5-methyl-5,7-dihydrofuro[3,4-d]pyrimidine, researchers have been able to develop analogs with enhanced selectivity and potency against specific kinases. For instance, derivatives of this compound have shown promise in inhibiting tyrosine kinases, which are overactive in many types of cancer.

The chloro substituent on the pyrimidine ring is particularly important in these contexts. It not only facilitates further functionalization but also contributes to the binding affinity of the resulting inhibitors by interacting with specific residues in the kinase active site. This has led to the development of several lead compounds that are currently undergoing preclinical evaluation for their antitumor activity.

In addition to its applications in oncology, 4-chloro-5-methyl-5,7-dihydrofuro[3,4-d]pyrimidine has also been explored as a component in antiviral agents. The structural motif present in this compound has been found to exhibit inhibitory effects against certain viral enzymes by competing with natural substrates or by inducing conformational changes that disrupt viral replication cycles. Recent studies have highlighted its potential in targeting RNA-dependent RNA polymerases (RdRp) found in viruses such as influenza and HIV.

The methyl group at the fifth position of the pyrimidine ring adds another layer of complexity to its reactivity. This group can participate in hydrogen bonding interactions with biological targets, thereby influencing the overall binding affinity and selectivity of derived compounds. Researchers have leveraged this feature to design molecules that exhibit improved pharmacokinetic profiles and reduced off-target effects.

The synthesis of 4-chloro-5-methyl-5,7-dihydrofuro[3,4-d]pyrimidine itself is an intriguing process that showcases modern synthetic methodologies. Traditional approaches often involve multi-step sequences involving cyclization reactions followed by functional group transformations. However, recent advancements have enabled more efficient synthetic routes that minimize intermediate steps and improve yields. These improvements are crucial for large-scale production and for facilitating further derivatization efforts.

The compound’s stability under various conditions is another important consideration. Studies have demonstrated that 4-chloro-5-methyl-5,7-dihydrofuro[3,4-d]pyrimidine maintains its integrity under standard storage conditions but can undergo degradation when exposed to extreme temperatures or acidic environments. Understanding these stability profiles is essential for optimizing both synthetic protocols and storage conditions to ensure consistent quality throughout drug development processes.

Efforts to enhance the sustainability of chemical synthesis have also focused on greener methodologies for producing 4-chloro-5-methyl-5,7-dihydrofuro[3,4-d]pyrimidine. Researchers are exploring alternative reaction conditions that reduce reliance on hazardous solvents or transition metals without compromising efficiency or yield. Such innovations align with broader trends toward environmentally responsible pharmaceutical manufacturing practices.

The future prospects for this compound remain promising as ongoing research continues to uncover new applications and synthetic strategies. Collaborative efforts between academic institutions and pharmaceutical companies are likely to yield novel derivatives with improved therapeutic profiles suitable for clinical use. As our understanding of biological systems evolves further refined tools like 4-chloro-5-methyl-5-hydrofuro[3 d]pyrimidin e will be instrumental in addressing unmet medical needs across multiple disease indications.

• 26639-92-9(Furo[3,4-d]pyrimidin-7(5H)-one)
• 36267-77-3(Furo[3,4-d]pyrimidine,5,7-dihydro-2,7-dimethyl-)
• 534599-89-8(2-Pyrimidinamine, 4-chloro-6-ethyl-5-(phenylmethyl)-)
• 127958-00-3(2-amino-4-(methoxymethyl)pyrimidine-5-carboxylic acid)
• 112476-74-1(2-amino-Furo[3,4-d]pyrimidin-5(7H)-one)
• 864439-37-2(FURO[3,4-D]PYRIMIDINE-2-CARBONITRILE, 5,7-DIHYDRO-)
• 36267-74-0(Furo[3,4-d]pyrimidine,5,7-dihydro-2-methyl-)
• 140655-23-8(Pyrimidine, 4-methyl-2-phenyl-5-[1-(2-propynyloxy)ethyl]-)
• 504404-53-9(Pyrimidine, 4-chloro-2-[4-(methoxymethyl)phenyl]-6-methyl-)
• 67602-27-1(Furo[3,4-d]pyrimidine, 5,7-dihydro-2,5,5,7,7-pentamethyl-)